---
title: "Krystal Biotech's Medicine to Treat Wounds in Dystrophic Epidermolysis Bullosa Gets Approval in UK"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286606318.md"
description: "Krystal Biotech's beremagene geperpavec has received approval from the UK's Medicines and Healthcare products Regulatory Agency for treating wounds in patients with dystrophic epidermolysis bullosa from birth. The gel showed a 67% complete healing rate in a study of 31 patients over six months. The stock price is currently at $308.93, down 2.33%."
datetime: "2026-05-15T19:36:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286606318.md)
  - [en](https://longbridge.com/en/news/286606318.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286606318.md)
---

# Krystal Biotech's Medicine to Treat Wounds in Dystrophic Epidermolysis Bullosa Gets Approval in UK

03:36 PM EDT, 05/15/2026 (MT Newswires) -- Krystal Biotech's ( KRYS ) beremagene geperpavec to treat wounds in patients with dystrophic epidermolysis bullosa has received approval from the UK's Medicines and Healthcare products Regulatory Agency for use from birth onward, the agency said in a Friday statement.

The medication, which is available in the form of gel, demonstrated 67% complete healing rate in a study of 31 patients at six months, according to the statement.

Dystrophic epidermolysis bullosa is a rare genetic condition characterized by fragile skin and recurrent wounds.

Price: 308.93, Change: -7.37, Percent Change: -2.33

MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.

### Related Stocks

- [KRYS.US](https://longbridge.com/en/quote/KRYS.US.md)

## Related News & Research

- [Entrada Therapeutics Highlights Transformational Year and Pipeline Progress](https://longbridge.com/en/news/286898145.md)
- [Nu Skin Reaches 900 Million Meals Purchased and Donated in its Global Fight for Child Nutrition | NUS Stock News](https://longbridge.com/en/news/286556034.md)
- [Lupin bets big on India's GLP-1 market & respiratory drugs](https://longbridge.com/en/news/287021542.md)
- [Sarepta's Elevidys Faces 'Little' Pressure After Regenxbio Data, Wedbush Says](https://longbridge.com/en/news/286589741.md)
- [00:45 ETAraceli Biosciences Launches Endeavor® Live Cell for Ultra-High-Throughput Kinetic Imaging in AI-Driven Drug Discovery](https://longbridge.com/en/news/287006505.md)